Table 3.
Hazard ratios (HR) with 95% confidence intervals (CI) of 5-year mortality after surgery for gastric non-cardia adenocarcinoma and gastric cardia adenocarcinoma 2005-2017. Observed 5-year survival after surgery stratified by tumor stage in 2005–2017. Observed 5-year survival stratified by tumor-stage for calendar period 2005–2009 and 2010–2013
| Gastric non-cardia adenocarcinoma | Gastric cardia adenocarcinoma | |||||||||
|---|---|---|---|---|---|---|---|---|---|---|
| Covariates | Number of patients (%) | Tumor stageb | Observed 5-year survival (95% CI) | Crude HR (95% CI) | Adjusted HR (95% CI)a | Number of patients (%) | Tumor stageb | Observed 5-year survival (95% CI) | Crude HR (95% CI) | Adjusted HR (95% CI)a |
| Tumor stageb | ||||||||||
| 0–I | 517 (34) | 58 (54–62) | 1 (Reference) | 1 (Reference) | 137 (24) | 64 (57–72) | 1 (Reference) | 1 (Reference) | ||
| II | 339 (22) | 41 (36–46) | 1.55 (1.28–1.88) | 1.61 (1.33–1.95) | 147 (26) | 35 (28–42) | 2.05 (1.45–2.89) | 2.09 (1.47–2.95) | ||
| III–IV | 684 (44) | 13 (11–15) | 3.72 (4.36) | 3.97 (3.39–4.65) | 279 (50) | 20 (16–25) | 3.47 (2.55–4.72) | 3.73 (2.73–5.10) | ||
| Calendar period | ||||||||||
| 2005–2009 | 893 (58) | 1.22 (1.07–1.38) | 1.30 (1.15–1.48) | 314 (56) | 1.22 (0.99–1.50) | 1.28 (1.04–1.58) | ||||
| 2010–2013 | 647 (42) | 1 (Reference) | 1 (Reference) | 249 (44) | 1 (Reference) | 1 (Reference) | ||||
| Age (years) | ||||||||||
| < 60 | 289 (26) | 1 (Reference) | 1 (Reference) | 157 (28) | 1 (Reference) | 1 (Reference) | ||||
| 60–69 | 394 (34) | 1.23 (1.01–1.51) | 1.20 (0.98–1.47) | 216 (38) | 1.22 (0.94–1.59) | 1.42 (1.08–1.86) | ||||
| 70–79 | 521 (22) | 1.43 (1.18–1.73) | 1.36 (1.12–1.66) | 155 (28 | 1.33 (1.00–1.76) | 1.52 (1.13–2–03) | ||||
| ≥ 80 | 336 (19) | 2.24 (1.83–2.73) | 2.24 (1.82–2.75) | 35 (6) | 1.81 (1.18–2.79) | 2.08 (1.33–3.23) | ||||
| Sex | ||||||||||
| Male | 872 (57) | 1 (Reference) | 1 (Reference) | 451 (80) | 1 (Reference) | 1 (Reference) | ||||
| Female | 668 (43) | 0.92 (0.81–1.04) | 0.94 (0.83–1.07) | 112 (20) | 0.76 (0.58–1.00) | 0.82 (0.62–1.08) | ||||
| Comorbidity score | ||||||||||
| 0 | 916 (59) | 1 (Reference) | 1 (Reference) | 355 (63) | 1 (Reference) | 1 (Reference) | ||||
| 1 | 436 (28) | 1.25 (1.09–1.44) | 1.19 (1.03–1.37) | 154 (27) | 1.17 (0.92–1.48) | 1.19 (0.93–1.52) | ||||
| ≥ 2 | 188 (12) | 1.40 (1.16–1.69) | 1.28 (1.05–1.55) | 54 (10) | 1.74 (1.25–2.41) | 1.49 (1.07–2.09) | ||||
| Calendar period | ||||||||||
| 2005–2009 | 306 | 0–I | 56 (50–61) | 71 | 0–I | 65 (54–76) | ||||
| 2005–2009 | 192 | II | 34 (27–41) | 85 | II | 39 (28–49) | ||||
| 2005–2009 | 395 | III–IV | 11 (8–14) | 158 | III–IV | 16 (10–22) | ||||
| 2010–2013 | 211 | 0–I | 59 (52–66) | 66 | 0–I | 62 (50–74) | ||||
| 2010–2013 | 147 | II | 53 (45–61) | 62 | II | 34 (21–47) | ||||
| 2010–2013 | 289 | III–IV | 18 (13–23) | 121 | III–IV | 28 (20–36) | ||||
aAdjusted for calendar period, age, sex, comorbidity, and tumor stage
b374 (19.5%) patients with gastric non-cardia adenocarcinoma and 69 (11%) patients with gastric cardia adenocarcinoma had missing tumor stage and are excluded from this analysis